Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

The phase III Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors Trial (BENEFIT‐EXT) study compared more or less intensive belatacept‐based immunosuppression with cyclosporine (CsA)–based immunosuppression in recipients of extended c...

Descripción completa

Detalles Bibliográficos
Autores principales: Florman, S., Becker, T., Bresnahan, B., Chevaile‐Ramos, A., Carvalho, D., Grannas, G., Muehlbacher, F., O'Connell, P. J., Meier‐Kriesche, H. U., Larsen, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215636/
https://www.ncbi.nlm.nih.gov/pubmed/27232116
http://dx.doi.org/10.1111/ajt.13886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215636/
https://www.ncbi.nlm.nih.gov/pubmed/27232116
http://dx.doi.org/10.1111/ajt.13886

Ejemplares similares